US2003130215A1PendingUtilityA1

Isolated genomic polynucleotide fragments from chromosome 7

Priority: Sep 21, 2000Filed: Sep 21, 2001Published: Jul 10, 2003
Est. expirySep 21, 2020(expired)· nominal 20-yr term from priority
Inventors:James W. Ryan
C12N 9/1205C12Q 1/6876A61P 43/00Y10T436/143333C12N 9/1241A61K 38/00C12N 9/48C07K 14/705
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human liver glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated genomic polynucleotide, said polynucleotide obtainable from human chromosome 7 having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: 
 (a) a polynucleotide encoding a polypeptide selected from the group consisting of human SNARE YKT6 depicted in SEQ ID NO:1, human liver glucokinase depicted in SEQ ID NO:2, human adipocyte enhancer binding protein depicted in SEQ ID NO:3 and DNA directed 50 kD regulatory subunit (POLD2) depicted in SEQ ID NO:4;    (b) a polynucleotide selected from the group consisting of SEQ ID NO:5 which encodes human SNARE YKT6 depicted in SEQ ID NO:1, SEQ ID NO:6 which encodes human liver glucokinase depicted in SEQ ID NO:2, SEQ ID NO:7 which encodes human adipocyte enhancer binding protein depicted in SEQ ID NO:3 and SEQ ID NO:8 which encodes DNA directed 50 kD regulatory subunit (POLD2) depicted in SEQ ID NO:4;    (c) a polynucleotide which is a variant of SEQ ID NOS:5, 6, 7, or 8;    (d) a polynucleotide which is an allelic variant of SEQ ID NOS:5, 6, 7, or 8;    (e) a polynucleotide which encodes a variant of SEQ ID NOS:1, 2, 3, or 4;    (f) a polynucleotide which hybridizes to any one of the polynucleotides specified in (a)-(e)    (g) a polynucleotide which is a reverse complement of the polynucleotides specified in (a)-(f);    (h) a polynucleotide selected from the group consisting of a polynucleotide which encodes human SNARE YKT6 with exons as depicted in Table 1, a polynucleotide which encodes human liver glucokinase with exons as depicted in Table 3; a polynucleotide which encodes human adipocyte enhancer binding protein with exons as depicted in Table 2 and a polynucleotide which encodes DNA directed 50 kD regulatory subunit (POLD2) with exons as depicted in Table 4 and    (i) containing at least 10 transcription factor binding sites selected from the group consisting of AP1FJ-Q2, AP1-C, AP1-Q2, AP1-Q4, AP4-Q5, AP4-Q6, ARNT-01, CEBP-01, CETS1P54-01, CREL-01, DELTAEF1-01, FREAC7-01, GATA1-02, GATA1-03, GATA1-04, GATA1-06, GATA2-02, GATA3-02, GATA-C, GC-01, GFII-01, HFH2-01, HFH3-01, HFH8-01, IK2-01, LMO2COM-01, LMO2COM-02, LYF1-01, MAX-01, NKX25-01, NMYC-01, S8-01, SOX5-01, SP1-Q6, SAEBP1-01, SRV-02, STAT-01, TATA-01, TCF11-01, USF-01, USF-C and USF-Q6.    
     
     
         2 . A nucleic acid construct comprising the polynucleotide of  claim 1 .  
     
     
         3 . An expression vector comprising the polynucleotide of  claim 1 .  
     
     
         4 . A recombinant host cell comprising the nucleic acid construct of  claim 2 .  
     
     
         5 . A recombinant host cell comprising the expression vector of  claim 4 .  
     
     
         6 . A method for obtaining a polypeptide encoded by a polynucleotide obtainable from human chromosome 7, said polypeptide selected from the group consisting of human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein and DNA directed 50 kD regulatory subunit (POLD2) comprising: 
 (a) culturing the recombinant host cell of  claim 5  under conditions that provide for the expression of said polypeptide and (b) recovering said expressed polypeptide.    
     
     
         7 . A method for preparing an antibody specific to a polypeptide selected from the group consisting of human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein and DNA directed 50 kD regulatory subunit (POLD2) comprising: 
 (a) obtaining a polypeptide according to the method of  claim 6;     (b) optionally conjugating said polypeptide to a carrier protein;    (c) immunizing a host animal with said polypeptide or polypeptide-carrier protein conjugate of step (b) with an adjuvant and    (d) obtaining antibody from said immunized host animal.    
     
     
         8 . An antisense oligonucleotide or mimetic to an isolated polynucleotide which hybridizes to a non-coding region of SEQ ID NOS:5, 6, 7 or 8, which non-coding region is selected from the group consisting of an intron, a splice junction, a 5′ non-coding region, a transcription factor binding region and a 3′ non-coding region.  
     
     
         9 . A method of diagnosing a pathological condition or susceptibility to a pathological condition in a subject comprising: 
 (a) determining the presence or absence of a mutation in the polynucleotide of  claim 1  and    (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.    
     
     
         10 . A composition comprising the polynucleotide of  claim 1  and a carrier.  
     
     
         11 . A composition comprising the antisense oligonucleotide of  claim 8  and a carrier.  
     
     
         12 . A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of  claim 10  effective to prevent, treat or ameliorate said medical condition.  
     
     
         13 . A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of  claim 11  effective to prevent, treat or ameliorate said medical condition.  
     
     
         14 . A kit comprising the polynucleotide of  claim 1 .  
     
     
         15 . The kit according to  claim 14 , in which the polynucleotide is labeled with a detectable substance.  
     
     
         16 . A kit comprising the antisense oligonucleotide or mimetic of  claim 8 .  
     
     
         17 . The kit according to  claim 16 , in which the antisense oligonucleotide is labeled with a detectable substance.  
     
     
         18 . An isolated polynucleotide which hybridizes to a transcriptional regulatory region of SEQ ID NOS:5, 6, 7 or 8.  
     
     
         19 . A nucleic acid construct comprising the polynucleotide sequence of  claim 18  operably linked to a polynucleotide sequence encoding a heterologous polypeptide.  
     
     
         20 . An expression vector comprising the nucleic acid construct of  claim 19 .  
     
     
         21 . A recombinant host cell comprising the nucleic acid construct of  claim 19 .  
     
     
         22 . A method for expressing a heterologous polypeptide sequence comprising (a) culturing the recombinant host cell of  claim 21  under conditions that provide for the expression of said polypeptide and (b) recovering said expressed polypeptide.

Join the waitlist — get patent alerts

Track US2003130215A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.